Posted by Michael Wonder on 18 May 2022
TLV reconsiders subsidy of CGRP inhibitors
18 May 2022 - TLV has started a review of the CGRP inhibitors.
TLV has monitored the use of the CGRP inhibitors and notes that the use and benefit of treatment is not in line with the assumptions made when the decision on subsidy was made.
